公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派3.5元（含税） | 6.14 | 0.92 | | 2024.12.31 | 10派5.8元（含税） | 10.17 | 1.78 | | 2024.06.30 | 10派3.5元（含税） | 6.14 | 1.08 | | 2023.12.31 | 10派5.8元（含税） | 10.18 | 1.35 | | 2022.12.31 | 10派2.9元（含税） | 5.09 | 0.72 | | 2021.12.31 | 10派2.9元（含税） | 5.07 | 0.74 | | 2020.12.31 | 10派2.3元（含税） | 4.02 | 0.92 | | 2019.12.31 | 10派2.8元（含税） | 4.90 | 0.97 | | 2018.12.31 | 10转增2派3.3元（含税） | 4.81 | 0.70 | | 2017.12.31 | 10转增5派7.2元（含税） | 7.00 | 1.25 ...

格隆汇8月19日丨华东医药(000963.SZ)公布2025年半年度报告，上半年公司实现营业收入216.75亿元， 同比增长3.39%；归属于上市公司股东的净利润18.15亿元，同比增长7.01%；归属于上市公司股东的扣 除非经常性损益的净利润17.62亿元，同比增长8.40%；基本每股收益1.0293元；拟向全体股东每10股派 发现金红利3.50元(含税)。 ...

（文章来源：智通财经） 华东医药8月19日披露半年报，公司上半年实现营业收入216.75亿元，同比增长3.39%；归属于上市公司 股东的净利润18.15亿元，同比增长7.01%；基本每股收益1.0293元。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月19日，华东医药发布公告称，2025年上半年实现营业 收入216.75亿元，同比增长3.39%；归属于上市公司股东的净利润为18.15亿元，同比增长7.01%；归属 于上市公司股东的扣除非经常性损益的净利润17.62亿元，同比增长8.4%。 ...

Core Viewpoint - Huadong Medicine reported a steady growth in its performance for the first half of 2025, with revenue and net profit showing positive year-on-year increases, indicating a robust operational trend and commitment to shareholder returns through dividends [1] Financial Performance - In the first half of 2025, Huadong Medicine achieved total revenue of 21.675 billion yuan, a year-on-year increase of 3.39% [1] - The company reported a net profit attributable to shareholders of 1.815 billion yuan, up 7.01% year-on-year, and a net profit excluding non-recurring items of 1.762 billion yuan, reflecting an 8.40% increase [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Segments - The core subsidiary, Zhongmei Huadong, maintained a strong growth trend with revenue of 7.317 billion yuan, a 9.24% increase year-on-year, and a net profit of 1.580 billion yuan, up 14.09% [2] - The second quarter alone saw revenue of 3.696 billion yuan, a 12.04% increase, and a net profit of 737 million yuan, reflecting a 16.34% growth [2] - Innovative product sales and agency services generated 1.084 billion yuan, marking a significant 59% year-on-year increase [2] Product Development and Innovation - The company is advancing its research and development efforts, with a 33.75% increase in R&D investment to 1.484 billion yuan in the first half of 2025 [4] - Direct R&D spending reached 1.174 billion yuan, a 54.21% increase, accounting for 15.97% of the pharmaceutical industrial revenue [4] - Huadong Medicine is developing over 80 innovative drug pipelines across three core therapeutic areas: oncology, endocrinology, and autoimmune diseases [4] Strategic Collaborations and Market Expansion - The CAR-T product, Zekai Ze (注射液), has received positive clinical feedback and is expanding its market coverage, with over 20 provinces certified for medical institution use [2] - The collaboration with Quanxin Biotech on the drug Seluxin has seen over 1,200 hospitals prescribing it since its approval in November 2024 [3] Industrial and Commercial Growth - The pharmaceutical commercial segment achieved revenue of 13.947 billion yuan, a 2.91% increase, with a net profit of 226 million yuan, up 3.67% [7] - The industrial microbiology segment reported sales of 368 million yuan, a 29% increase year-on-year, focusing on xRNA raw materials and other core business areas [7] - The aesthetic medicine sector has established a comprehensive high-end product line, with 40 international products, 26 of which are already on the market [7]

（记者 王晓波） 每经AI快讯，华东医药（SZ 000963，收盘价：45.93元）8月19日晚间发布公告称，公司第十一届2025 年第一次董事会会议于2025年8月18日在公司会议室以通讯的方式召开。会议审议了《关于与专业投资 机构共同投资设立专项医药产业投资基金暨关联交易的议案》等文件。 截至发稿，华东医药市值为806亿元。 每经头条（nbdtoutiao）——热浪"烤"验全球，近10年我国年平均高温日数增多25%！高温对经济的搅动 作用越发强烈，国家气候中心六位专家详解高温经济学 ...

Group 1 - The company, Huadong Medicine (000963.SZ), announced its participation as a limited partner in a new investment fund, "Hangzhou Fuguang Hongze Equity Investment Partnership (Limited Partnership)" [1] - The total committed capital for the fund is RMB 2 billion, with the company contributing RMB 980 million, representing a 49% stake [1] - The investment focus of the fund includes innovative pharmaceuticals, medical aesthetics, health and wellness, animal health, and other sectors related to biology, medicine, and health that align with Hangzhou's five major industrial ecosystems [1]

Core Insights - Company reported a revenue of 21.675 billion with a year-on-year growth of 3.39% [1] - Net profit attributable to shareholders reached 1.815 billion, reflecting a year-on-year increase of 7.01% [1] - Basic earnings per share stood at 1.03 yuan [1] Financial Performance - The company plans to distribute a cash dividend of 3.5 yuan per 10 shares (tax included) [1] - Revenue from sales and agency services amounted to 1.084 billion, with a significant year-on-year growth of 59% [1] - The company is benefiting from the approval and launch of new products, contributing to the growth in innovative product revenue [1]

第十一届董事会独立董事专门会议2025年第一次会议决议 华东医药股份有限公司（以下简称"公司"）第十一届董事会独立 董事专门会议 2025 年第一次会议于 2025 年 08 月 18 日（星期一）在 公司会议室以通讯的方式召开。会议通知已于 2025 年 08 月 15 日通 过邮件的方式送达各位独立董事。本次会议应出席独立董事 4 人，实 际出席独立董事 4 人。 会议由全体独立董事共同推举黄简女士担任召集人和主持人。会 议召开符合有关法律、法规、规章和《公司章程》《独立董事工作制 度》的规定。经各位独立董事认真审议，会议形成了如下决议： 1、审议通过《关于与专业投资机构共同投资设立专项医药产业 投资基金暨关联交易的议案》 表决结果：4 票同意，0 票反对，0 票弃权。 华东医药股份有限公司 独立董事： 黄简 王如伟 魏淑珍 薛丽香 2025 年 08 月 20 日 本次公司参与投资设立生物医药产业投资基金暨关联交易，有利 于公司借助专业机构的投资经验和能力，提高对投资标的运作的专业 性，不会对公司的独立性构成影响，符合公司及全体股东的利益，有 利于公司的长远发展。本次关联交易对公司日常经营及财务状况不会 ...

Core Viewpoint - Huadong Medicine reported a steady growth in its financial performance for the first half of 2025, with revenue reaching 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit of 1.815 billion yuan, up 7.01% [1] Financial Performance - The company achieved a total revenue of 21.675 billion yuan in the first half of 2025, reflecting a 3.39% increase year-on-year [1] - The net profit attributable to shareholders was 1.815 billion yuan, marking a 7.01% growth, while the net profit excluding non-recurring items was 1.762 billion yuan, up 8.40% [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Growth and Product Commercialization - Huadong Medicine's core subsidiary, Zhongmei Huadong, reported a revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [2] - The innovative product sales and agency service revenue reached 1.084 billion yuan, with a significant growth of 59% [2] - The CAR-T product, Zekai Ze, has expanded its market coverage, with over 20 provinces certified and more than 100 insurance projects included for reimbursement [2] R&D and Innovation - The company invested 1.484 billion yuan in R&D, a 33.75% increase, with direct R&D spending at 1.174 billion yuan, up 54.21% [6] - Huadong Medicine is advancing over 80 innovative drug pipelines, focusing on oncology, endocrinology, and autoimmune diseases [6][7] - The ADC product pipeline is progressing well, with several candidates in clinical trials and receiving orphan drug designation from the FDA [8] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment achieved sales of 368 million yuan, a 29% increase, with significant growth in various sub-segments [10] - The aesthetic medicine division has launched multiple products, with strong market reception and ongoing registration efforts for new products [11][12] - The company aims to enhance its global presence and continue driving innovation in both pharmaceutical and aesthetic sectors [12]